The stock carries a Zacks #3 Rank (Hold rating) in the short run. The Zacks Consensus Estimate for 2011 currently hints at earnings of $4.59 per share on revenues of $2.7 billion. The company continues to expect earnings (on an adjusted basis) in the range of $4.55-$4.65 per share on revenues of $2.72-$2.80 billion. Endo Pharma completed three major acquisitions in 2010.Īpart from announcing financial results, Endo Pharma reaffirmed its 2011 guidance. We note that the purchase of American Medical is the fourth major acquisition by Endo Pharma over the last one year. The remaining revenues (approximately 29%) from the segment came from HealthTronics, a provider of urology products and services, which was acquired by Endo Pharma in July 2010. Revenues were boosted by the acquisition of American Medical Systems, a leading pelvic-health devices provider, in June 2011. Revenues from devices and services came in at $185.6 million in the reported quarter, up 259% year over year. Endo currently has approximately 50 abbreviated new drug applications (ANDAs) under review by the US Food and Drug Administration (:FDA). The generic segment was boosted by the acquisition of privately-held generic company Qualitest Pharmaceuticals in December 2010. The sale of generic products at Endo jumped 439% to $148.0 million in the reported quarter. The impressive showing by key products in the pain franchise drove the increase. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.The third quarter witnessed a 17% rise in the sale of branded drugs to $425.5 million. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Our proven model does not predict an earnings beat for Endo this season. Investors will focus on further updates on the same. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Florida. Other UpdatesĮndo announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc. Hence, the total revenues are expected to have recorded sequential growth. Revenues for 2021 are projected to be $2.90-$2.94 billion compared with the earlier estimated range of $2.73-$2.79 billion. International Pharmaceuticals revenues declined in the previous quarter, and the same trend is likely to have prevailed in the fourth quarter.Ĭoncurrent with the third-quarter results, Endo upped its annual revenue projections. The fourth quarter is likely to have witnessed similar or higher levels of growth. Generic Pharmaceuticals reported 29% growth in the third quarter revenues due to additional revenues from the 2021 product launches. This trend is expected to have continued in the fourth quarter. Total revenues during the third quarter of 2010 increased 23 percent to 444.1 million, compared with 361.0 million in the same quarter of 2009. Sterile Injectables’ revenues jumped 37% year over year in the previous quarter due to increased Vasostrict revenues. Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the third quarter 2010. However, Established Products revenues decreased 17% in the third quarter, and revenues from this franchise might have declined this time as well. Sales of Xiaflex increased 20% in the previous quarter, and the drug is likely to have recorded sequential growth in the fourth quarter. Within the segment, Specialty Products revenues increased 16% in the prior quarter. Image Source: Zacks Investment Research Factors at PlayĮndo has four reportable business segments - Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.īranded Pharmaceuticals’ revenues were up 3% in the third quarter, and similar levels of growth might have been registered in the fourth quarter. As Peter mentioned earlier, Endo’ net sales for the third quarter of 2007 were record 269.5 million prepared with 217.1 million in the third quarter of. Shares of Endo’s have lost 69.2% in the past year compared with the industry’s decline of 31.3%.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |